Tirapazamine-induced DNA damage measured using the comet assay correlates with cytotoxicity towards hypoxic tumour cells in vitro
1996

Tirapazamine and DNA Damage in Tumor Cells

publication Evidence: moderate

Author Information

Author(s): BG Siim, PL van Zijl, JM Brown

Primary Institution: Stanford University School of Medicine

Hypothesis

Can the comet assay predict the response of individual tumors to tirapazamine based on DNA damage?

Conclusion

The study found a strong correlation between tirapazamine-induced DNA damage and its cytotoxic effects on hypoxic tumor cells.

Supporting Evidence

  • The correlation between hypoxic cytotoxic potency of tirapazamine and DNA damage was highly significant (r=0.905, P=0.013).
  • Tirapazamine exhibits high hypoxia-selective cytotoxicity in the order of 50 to 200-fold in most rodent and human cell lines.
  • The study suggests that the comet assay may be used as a predictive assay for tumor response to tirapazamine.

Takeaway

This study shows that measuring DNA damage can help predict how well a cancer drug called tirapazamine will work on different tumors.

Methodology

The study used the comet assay to measure DNA damage and high-performance liquid chromatography (HPLC) to analyze drug metabolism in various tumor cell lines under hypoxic conditions.

Limitations

The study was limited to a small number of cell lines and may not represent all tumor types.

Statistical Information

P-Value

0.013

Statistical Significance

p=0.013

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication